



Universiteit
Leiden
The Netherlands

Non-ribose ligands for the human adenosine A1 receptor

Klaase, E.C.

Citation

Klaase, E. C. (2008, June 10). *Non-ribose ligands for the human adenosine A1 receptor*. Retrieved from <https://hdl.handle.net/1887/12936>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/12936>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER 4

Allosteric modulators affect the internalization of
human adenosine A₁ receptors

To study the effect of allosteric modulators on the internalization of human adenosine A₁ receptors, the receptor was equipped with a C-terminal yellow fluorescent protein tag. The introduction of this tag did not affect the radioligand binding properties of the receptor. CHO cells stably expressing this receptor were subjected during 16 h to varying concentrations of the agonist *N*⁶-cyclopentyladenosine (CPA) in the absence or presence of 10 μM of the allosteric enhancer PD81,723 ((2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)phenyl]methanone) or SCH-202676 (*N*-(2,3-diphenyl-1,2,4-thiadiazol-5(2*H*)-ylidene)methanamine). CPA itself was able to internalize 25% and 40% of the receptors at a concentration of 400 nM or 4 μM, respectively. Addition of either PD81,723 or SCH-202676 alone had no effect on internalization. However, with PD81,723 a slight amount of internalization was obtained already at 40 nM of CPA, and at 400 nM CPA 59% of the receptors internalized. SCH-202676 on the other hand effectively prevented CPA-induced internalization of the receptor.

Based upon Klaasse EC, van den Hout G, Roerink SF, de Grip WJ, IJzerman AP, Beukers MW., Eur J Pharmacol. 2005, 522:1-8.

Introduction

Adenosine receptors are members of the superfamily of G protein-coupled receptors (GPCRs) and are pharmacologically classified into four distinct types, namely the adenosine A₁, A_{2A}, A_{2B} and A₃ receptor. Adenosine A₁ and A₃ receptors are coupled to a G_i protein, thereby inhibiting the production of cAMP via adenylyl cyclase. In contrast, adenosine A_{2A} and A_{2B} receptors are coupled to a G_s protein, thereby stimulating the production of cAMP (for review on adenosine receptors, see Fredholm et al.)¹.

Like other members of the GPCR family, adenosine receptors are subject to allosteric modulation (for reviews on allosteric modulation, see Soudijn et al.; Christopoulos and Kenakin)^{2,3}. PD81,723 ((2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)phenyl]-methanone) is an allosteric enhancer selectively exerting its action on the adenosine A₁ receptor. It potentiates the agonist binding, thereby enhancing the functional effects of adenosine or its analogues⁴. It has also been reported that PD81,723 potentiates constitutive activity of the adenosine A₁ receptor⁵. SCH-202676 (*N*-(2,3-diphenyl-1,2,4-thiadiazol-5(2*H*)-ylidene)methanamine) on the other hand inhibits both agonist and antagonist binding to a number of GPCRs such as human μ -, δ -, and κ -opioid, α - and β -adrenergic, muscarinic M₁ and M₂, and dopaminergic D₁ and D₂ receptors⁶, including adenosine receptors^{7,8}. Recent studies revealed that SCH-202676 and analogues are not strict allosteric modulators as originally thought, but rather sulfhydryl modifying agents that reversibly modify cysteine residues in proteins^{9,10}.

Adenosine receptors, like other GPCRs, undergo internalization upon agonist stimulation. Internalization or sequestration is described as the loss of cell surface receptor number, determined by the combined effects of endocytosis and recycling¹¹. In the present study, we focus on the internalization of the human adenosine A₁ receptor. The process of internalization has been shown to be initiated by the functional desensitization of the adenosine A₁ receptor. After a short period of agonist exposure (5-15 min), the adenosine A₁ receptors uncouple from the G_i proteins due to phosphorylation, catalyzed by specific receptor kinases¹²⁻¹⁵. Especially serine and threonine residues close to the C-terminus of the receptor are susceptible to phosphorylation^{12,16}. Upon phosphorylation of the adenosine A₁ receptor, β -arrestins are attracted, which couple to the phosphorylated receptor. β -arrestins do not only desensitize the receptor, but also function as clathrin adaptors thereby inducing the process of sequestration and internalization. Although phosphorylation of the adenosine A₁ receptor returned to its basal state within minutes, the desensitization continued for hours. Unlike the uncoupling, $t_{1/2}$ for the internalization process of the adenosine A₁ receptor is quite slow, 10 ± 1 h¹⁴. In contrast, $t_{1/2}$ for internalization of the other G_i coupled adenosine receptor (A₃ receptor) is short, only 10 min¹⁶.

In the present study, we have examined whether allosteric modulators are able to influence the internalization of the human adenosine A₁ receptor. To visualize this process, we engineered a yellow fluorescent protein (YFP) C-terminal of the human adenosine A₁ receptor. Our findings indicate that the presence of the allosteric enhancer PD81,723 lowers the threshold of agonist concentration at which receptor internalization occurs. In contrast, the presence of SCH-202676 almost completely prevented internalization of the human adenosine A₁ receptor.

Materials and methods

Materials

N⁶-cyclopentyladenosine (CPA) was obtained from Research Biochemicals Inc. (Natick, MA, U.S.A.). 8-cyclopentyl-1,3-cyclopentyladenosine ([³H]DPCPX -specific activity 124 Ci/mmol) was purchased from NEN (Du Pont Nemours, 's Hertogenbosch, The Netherlands). G418 (neomycin) was obtained from Stratagene (Cedar Creek, U.S.A.). (2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)phenyl]methanone (PD81,723) and (*N*-(2,3-diphenyl-1,2,4-thiadiazol-5(2*H*)-ylidene)methanimine (SCH-202676) were synthesized in our own laboratory as described by Van der Klein et al.¹⁸ and Van den Nieuwendijk et al.⁷ respectively. All other chemicals were of analytical grade and obtained from standard commercial sources.

Construction of human adenosine A₁YFP receptor

The human adenosine A₁ receptor cDNA (1.3 kb) was isolated from pcDNA3 (Invitrogen BV, Breda, The Netherlands) and inserted into the pBluescript II SK (-) vector (Stratagene, Cedar Creek, USA) using *Hind*III/*Xba*I sites. A reverse primer was designed to mutate the stop codon, introduce an extra base and an *Apal* site at the 3' end: 3' gggctctctctccggactactgcccccggcgc 5' (*Apal* restriction site is underlined). The human adenosine A₁ receptor cDNA was amplified by a polymerase chain reaction (PCR) using a universal forward primer (un-4) for pBlueScript II SK(-) and the designed reverse primer. The PCR product was purified on gel and subcloned into the pYFP-N1 vector digested with *Hind*III/*Apal* (kindly provided by C. Backendorf, Leiden University), resulting in a human adenosine A₁YFP receptor construct.

Cell culture

CHO cells were cultured in a humidified atmosphere at 37 °C and 5% CO₂ in a 1:1 mixture of Dulbecco's Modified Eagle Medium (DMEM) and Ham's F12 medium, containing 10% newborn calf serum, 50 IU/ml penicillin, 50 µg/ml streptomycin and

0.8 µg/ml G418 for selection. CHO cells were stably transfected with the human adenosine A₁YFP receptor construct, using 1mg/ml *N*-(2,3-dioleoyloxy-1-propyl)trimethylammonium methyl sulfate (DOTAP) as described by Beukers et al.¹⁹. In short, 5 × 10⁴ cells per well (24 wells plate) were seeded the day before transfection. For each well, 2.3 µL DOTAP (1 mg/ml) plus 0.7 µg human adenosine A₁YFP receptor cDNA was added to 50 µL DMEM without serum. Liposomes were formed during 20 min at room temperature. Cells were washed twice with DMEM without serum, next 50 µL DMEM without serum was added followed by the transfection mix. Cells were left for 2 h at 37 °C, 5% CO₂. Subsequently, the cells were washed with phosphate buffered saline (PBS) and treated with 5% Dimethyl Sulfoxide (DMSO) in PBS for 3 min. The DMSO mixture was removed and 500 µL of a 1: 1 mixture of DMEM/F12 medium, containing 10% newborn calf serum, 2 mM glutamax, 50 IU/ml penicillin and 50 mg/ml streptomycin was added per well. G418 (0.8 mg/ml) was added to the medium to select for cells that had taken up the plasmid. The medium was replaced every other day. After 10 days, individual colonies were selected and transferred to separate wells in a 24 wells plate. Radioligand binding experiments were performed to select a clone with a sufficiently high expression level of the human adenosine A₁YFP receptor. This clone was used for internalization experiments. Cells were subcultured twice a week (1:40).

Preparation of cell membranes

CHO cells stably expressing the wt human adenosine A₁ receptor were obtained from A. Townsend-Nicholson²⁰. Confluent CHO cells expressing either the wt human adenosine A₁ receptor or the human adenosine A₁YFP receptor were scraped in PBS and centrifuged for 10 min at 250 g. The cell pellets were resuspended in ice-cold Tris-HCl buffer, 50 mM, pH 7.4, and homogenized on ice for 5 s at position 8 using an Ystral homogenizer. The homogenates were centrifuged for 45 min at 17000 g at 4 °C. The resulting pellets were resuspended in Tris-HCl buffer, 50 mM, pH 7.4, and 2 IU/ml adenosine deaminase was added. Aliquots were stored at -80 °C. The protein concentration of the membranes was measured using the BCA method²¹.

Receptor binding assays

Radioligand displacement experiments were performed with minor modifications as described previously for the wt human adenosine A₁ receptor in CHO cells²². In brief, membranes (10 µg protein) were incubated in 400 µL Tris-HCl buffer, 50 mM, pH 7.4, in the presence or absence of 10 µM PD81,723 or 10 µM SCH-202676 and in the presence of 1.6 nM [³H]DPCPX and increasing concentrations of CPA. Non-specific binding was determined in the presence of 1 × 10⁻⁴ M CPA. For saturation experiments, concentrations of [³H]DPCPX ranged from 0.1 to 10 nM. Samples were

incubated at 25 °C for 1 h in a shaking water bath and the incubation was terminated by adding 1 ml of ice-cold Tris-HCl, 50 mM, pH 7.4 followed by rapid filtration over Whatman GF/B glass-fiber filters. Filters were washed three times with 2 ml of ice cold Tris-HCl buffer and placed in scintillation vials. For saturation experiments, filters were washed six times with 2 ml of ice cold Tris-HCl buffer. Scintillation fluid (Emulsifier Safe, Packard BioScience), 3.5 ml, was added and after 2 h extraction, radioactivity was counted in an LKB Wallac 1219 rackbeta scintillation counter. Experiments were performed in triplicate.

Internalization experiments

CHO cells stably expressing the human adenosine A₁YFP receptor were plated on coverslips in 24 wells plates at a density of 3×10^4 cells/well in a volume of 0.5 ml. The cells were allowed to attach for 24 h, after which the medium was aspirated and the cells were exposed for 16 h to 0 nM, 40 nM, 400 nM, 4 μM CPA in the presence or absence of 10 μM PD81,723 or 10 μM SCH-202676. Cells were washed once with 0.5 ml PBS, and fixed with 0.5 ml 4.0% formaldehyde (pH 7.0-7.2) for 10 min at room temperature. Coverslips containing the cells were washed another 3 times with 0.5 ml PBS and subsequently mounted on object glasses using Aqua Polymount[®] (Polysciences). Coverslips were allowed to dry on air in darkness, and stored at 4 °C for short term storage or -20 °C for long term storage. Images of the incubated cells were obtained using confocal microscopy (Nikon Eclipse TE 2000-U), excitation at 520 nm, emission at 532 nm, 60x oil enlargement.

Quantification of internalization

The computer program Image Pro Plus (MediaCybernetics, Germany) was used to quantify the amount of fluorescence in representative transsections of cells. The amount of fluorescence in the cell membrane was determined and expressed as percentage of the total fluorescence and was corrected for the differences in surface area of the transsection. Transsections of at least three different cells were analyzed.

Quantification of internalization through radioligand binding

In addition, the amount of internalization was quantified with help of radioligand binding experiments. Therefore, confluent 10 cm plates of CHO cells stably expressing the human adenosine A₁YFP receptor were incubated with or without 4 μM CPA for 16 hrs. Both were washed once with 5 ml PBS and subsequently scraped in 5 ml PBS. The preparation of the membranes was performed as described in section 2.4. The only modification was that the homogenates were centrifuged for 2 x 20 min at 17000 g at 4 °C. Radioligand binding studies were

performed on membranes of the control cells as well as the exposed cells as described in section 2.5.

Data analysis

Data of radioligand binding- and saturation experiments were analysed using the non-linear regression curve fitting program Prism v. 3.0 (GraphPad, San Diego, CA, USA). Apparent inhibitory binding constants (K_i values) were derived from the IC_{50} values according to the Cheng and Prusoff equation $K_i = IC_{50}/(1 + [L^*]/K_D)$ where $[L^*]$ is the concentration of the radioligand and K_D its dissociation constant²³.

Results

Binding profile of wt human adenosine A₁ receptors and human adenosine A₁YFP receptors, stably expressed in CHO cells.

First, we assessed the affinity and binding capacity of the radioligand [³H]DPCPX for the human adenosine A₁YFP receptor. In Table 4.1, the K_d and B_{max} values of [³H]DPCPX for the human adenosine A₁YFP receptor in the presence or absence of PD81,723 and SCH-202676 are shown. The K_d value of [³H]DPCPX for the human adenosine A₁YFP receptor was hardly affected by the addition of PD81,723 and SCH-202676. The B_{max} value was slightly but not significantly lowered in the presence of PD81,723. Subsequently, radioligand binding studies were performed on membranes of human adenosine A₁YFP-CHO cells to characterize the binding properties of the newly constructed human adenosine A₁YFP receptor. In Figure 4.1, displacement curves for the human adenosine A₁YFP receptor are shown. Displacement experiments were performed using the reference agonist CPA alone, and CPA in the presence of 10 μ M PD81,723 or 10 μ M SCH-202676.

Table 4.1. Saturation parameters of [³H]DPCPX on CHO-hA₁YFP cell membranes

Compound	K_d (nM)	B_{max} (fmol/mg)
Control	1.45 ± 0.05	862 ± 50
+ PD81,723 (10 μ M)	1.51 ± 0.15	669 ± 55
+ SCH-202676 (10 μ M)	1.21 ± 0.09	805 ± 127

B_{max} and K_d -values of [³H]DPCPX in the absence or presence of PD81,723 (10 μ M) or SCH-202676 (10 μ M) on CHO-hA₁YFP cell membranes were determined. Values are the means (\pm S.E.M.) of three independent experiments, performed in duplicate. None of the determined values is significantly different compared to the control values, $P > 0.05$.

[³H]DPCPX was used as radioligand. The binding properties of the human adenosine A₁YFP receptors were compared with the binding profile of the wt human adenosine A₁ receptors. Like the wt human adenosine A₁ receptor, the human adenosine A₁YFP shows a biphasic behaviour towards CPA binding, and is also susceptible to allosteric modulation. PD81,723, the allosteric enhancer, shifts the CPA-curve to the left (gain of affinity) whereas in the presence of SCH-202676 the CPA-curve is shifted to the right (loss of affinity). In addition, the high affinity state of the human adenosine A₁YFP receptor was shifted to the low affinity state in the presence of SCH-202676. K_i-values of CPA for the human adenosine A₁YFP receptor in the presence or absence of PD81,723 and SCH-202676 are shown in Table 4.2. The shifts in the K_i-values of CPA were 0.24 and 4.0 for the human adenosine A₁YFP receptor in the presence of PD81,723 or SCH-202676, respectively.




Figure 4.1. Displacement of [³H]DPCPX with CPA (■) only, or in the presence of 10 μM PD81,723 (○) or 10 μM SCH-202676 (●). Membranes (10 μg) were incubated for 60 min at 25 °C as described in section 2.5. The graph is the mean of three displacement curves of the specific binding of [³H]DPCPX to CHO-hA₁YFP membranes, each performed in duplicate.

Table 4.2. K_i values of CPA in the presence or absence of 10 μM PD81,723 or 10 μM SCH-202676 for hA₁YFP receptors expressed in CHO cells.

K _i low (nM)	CHO-A ₁ YFP				
	K _i low (nM)	K _i high (nM)	Fraction high (%)	K _i (nM)	Shift
CPA	154 ± 9.5	0.61 ± 0.20	37 ± 2.0	42.5 ± 7.2	
CPA + PD81,723	47 ± 7.8	0.40 ± 0.12	40 ± 5.4	10.4 ± 3.3	0.24
CPA + SCH-202676				172 ± 28	4.0

The affinity of CPA for the hA₁YFP-receptors in the presence or absence of different modulators was determined by its displacement of [³H]DPCPX binding. Membranes (10 μg) were incubated for 60 min at 25 °C with CPA (in the presence or absence of PD81,723 and SCH-202676 as described in section 2.5. K_i values ± S.E.M. were calculated from three independent experiments. Shifts were calculated by dividing the K_i value in the presence of allosteric modulator by the K_i-value of CPA alone. To calculate the K_i values, the respective K_d values (Table 4.1) were used.

Internalization of the human adenosine A₁YFP receptors

The internalization of human adenosine A₁YFP receptors induced by CPA, and the influence of PD81,723 and SCH-202676 on this process, was investigated. First, we determined the time-course needed to observe proper internalization. We incubated CHO cells stably expressing the human adenosine A₁YFP receptor at increasing CPA concentrations for the following time points; 0, 2, 4, 6, 8, 16, 24 hours, and observed them with help of fluorescence microscopy. From these experiments it appeared that clear internalization was only observed after at least 16 hours of incubation (results not shown), which is in agreement with the fact that the $t_{1/2}$ for the internalization process of the adenosine A₁ receptor is $10 \pm 1 \text{ h}^{14}$. Additionally, we observed that the presence of the allosteric modulator PD81,723 (10 μM) did not accelerate the occurrence of internalization, but only increased the amount of internalized receptors (data not shown).

Subsequently, human adenosine A₁YFP-CHO cells were plated on coverslips and incubated for 16 hours with CPA in a concentration range of 0 nM, 40 nM, 400 nM and 4 μM , in the presence or absence of 10 μM PD81,723 or 10 μM SCH-202676. Several confocal images were made from each incubation, and representative transsections are shown in Figure 4.2. Control human adenosine A₁YFP-CHO cells show a clear, equally distributed membrane staining. The lowest CPA concentration (40 nM, approximate K_T -value) did not induce internalization of the human adenosine A₁YFP receptor. At 400 nM CPA (approx. $10 \times K_i$), internalization of the human adenosine A₁YFP receptor was apparent as green fluorescent dots in the cytoplasm. This effect was more distinct at the highest concentration CPA (4 μM , approx. $100 \times K_i$). In the presence of the allosteric enhancer PD81,723 (10 μM) at the lowest CPA concentration (40 nM), membrane staining was not as equally distributed as in the control cells. The internalization of the human adenosine A₁YFP receptor at CPA concentrations of 400 nM and 4 μM in the presence of PD81,723 was more substantial than internalization with CPA alone. Incubation of human adenosine A₁YFP-CHO cells in the presence of SCH-202676 (10 μM) almost completely prevented the internalization of the human adenosine A₁YFP receptors. No internalization was observed, except for the highest concentration of CPA (4 μM) where SCH-202676 was not able to completely prevent the internalization of the human adenosine A₁YFP receptors. PD81,723 or SCH-202676 alone did not induce internalization.




Figure 4.2. Confocal fluorescent pictures of internalized hA₁YFP receptors in CHO cells. hA₁YFP CHO cells were incubated for 16 hours with increasing concentrations of CPA in the presence or absence of PD81,723 (10 μ M) and SCH-202676 (10 μ M). Pictures were taken from a representative transsection of the cell.

Quantitative analysis of internalization

The amount of receptor internalization was quantified with help of the computer program Image Pro Plus. In Figure 4.3, the remaining fluorescence in the cell membrane is represented as a bar graph. At least three transsections of independent cells were quantified. Control human adenosine A₁YFP-CHO cells as well as cells exposed to either one of the compounds showed between 84% and 88% fluorescent membrane staining. The 40 nM CPA incubation showed only 11% internalization in the presence of 10 μ M PD81,723, the membrane staining was reduced from 88% to 77%. However, this reduction was not significant. CPA alone (40 nM) and in the presence of SCH-202676 (10 μ M) showed values comparable to control cells for membrane staining (resp. 87% and 84%). Exposure to 400 nM CPA reduced the membrane staining from 88% to 63% (25% internalization), whereas the addition of 10 μ M PD81,723 reduced the membrane staining even further to 29% (59% receptor internalization). SCH-202676 counteracted the effect of 400 nM CPA, such that no internalization was observed (90% fluorescence in the membrane). Exposure to 4 μ M CPA reduced membrane staining from 88% to 48%, whereas the addition of 10 μ M PD81,723 reduced this percentage to 27% (61% internalized human adenosine A₁YFP receptors), yielding approximately the same amount of internalized receptors

as obtained after incubation with 400 nM CPA plus PD81,723. Incubation with 4 μ M CPA in the presence of 10 μ M SCH-202676 led to a marginal, non-significant, reduction of membrane staining from 84% to 74%.




Figure 4.3. Quantitative analysis of the internalization of human adenosine A₁YFP-receptors in CHO cells. This bar graph corresponds with the confocal pictures shown in figure 2. The bars represent the percentage fluorescence in the cell membrane. Transsections of at least three different cells were analyzed. Values are means \pm S.E.M. ** $P \leq 0.005$, *** $P \leq 0.0005$, percentage fluorescence compared to the percentages fluorescence of corresponding incubations in the absence of CPA. ## $P \leq 0.005$ compared to the percentage fluorescence of the respective internal control (equal CPA concentration).

Confirmation of these results was obtained by performing radioligand binding studies on plasma membranes of human adenosine A₁YFP-CHO cells, exposed to 4 μ M CPA for 16 hours. The percentage of internalization measured as decrease of radioligand binding compared to control (i.e. cells treated identically but without CPA present) was $32 \pm 1\%$, corresponding very well to the 40% internalization measured by confocal microscopy.

Discussion

The introduction of a yellow fluorescent protein at the C-terminus of the human adenosine A₁ receptor and stable transfection of this human adenosine A₁YFP receptor into CHO cells, provided us with a tool to study internalization of the human adenosine A₁ receptor. By making the human adenosine A₁ receptor visible, there is no need to add fluorescent antibodies or gold particles as has been described before to visualize the internalization of the adenosine A₁ receptors^{12,14,24-26}.

Saturation experiments revealed that the addition of YFP to the C-terminus of the adenosine A₁ receptor did not affect the K_d value of [³H]DPCPX for the human

adenosine A₁YFP receptor (1.45 ± 0.05 vs 1.6 ± 0.1 nM for the wt human adenosine A₁ receptor²²). The addition of the allosteric modulator PD81,723 or SCH-202676 also hardly affected the K_d-value (1.51 ± 0.15 and 1.21 ± 0.09 nM, respectively, see Table 4.1). However, in the presence of PD81,723, the B_{max} value was slightly lower, 669 ± 55 fmol/mg vs 862 ± 50 fmol/mg for control, although these values did not differ significantly. Similar effects of PD81,723 on B_{max} and K_d values for the wt human adenosine A₁ receptor had been found by Battacharya and Linden²⁷ and Kollias-Baker et al.⁵.

As is shown in Figure 4.1 and Table 4.2, the addition of the C-terminal YFP did not markedly influence the binding properties of the adenosine A₁ receptor. The human adenosine A₁YFP receptor showed a two state binding curve, similar as described for the wild-type human adenosine A₁ receptor²⁸. The fraction of high affinity receptors was 37–40% for the human adenosine A₁YFP receptors, stably expressed in CHO cells. Slightly higher percentages of wild-type human adenosine A₁ receptors in the high affinity state were found by Musser et al.⁴ and Dalpiaz et al.²⁸, 52% and 74% respectively. The addition of PD81,723 did not increase the number of human adenosine A₁YFP receptors in the high affinity state, in accordance with experiments by Musser et al.⁴.

The affinity of CPA for the human adenosine A₁YFP receptor is in the same order of magnitude as reported in the literature for the wt human adenosine A₁ receptor. The K_i value for the low affinity state was 154 ± 9.5 nM vs 76 ± 6 nM for the wt human adenosine A₁ receptor and the K_i value for the high affinity state was 0.61 ± 0.2 nM vs 2.8 ± 0.2 nM for the wt human adenosine A₁ receptor, respectively²⁸. We observed a shift in affinity caused by the addition of PD81,723 of 0.30 for the low affinity state, and of 0.66 for the high affinity state, respectively. This corresponds well with the values found by Musser et al.⁴, reporting shifts for the wt human adenosine A₁ receptor of 0.29 and 0.57, respectively. The addition of SCH-202676 caused a shift towards the low affinity state, resulting in a one-site binding curve with a K_i value of 172 ± 28 nM. This is in the same order of magnitude as the K_i value found by Heitman (personal communication) for binding of CPA in the presence of SCH-202676 to the wt human adenosine A₁ receptor, 225 ± 8 nM. SCH-202676 inhibited the binding of the agonist CPA to the human adenosine A₁YFP receptor with a shift of 4. This is in accordance with the results found by van den Nieuwendijk et al., who observed that the binding of the agonist radioligand [³H] 2-Cl-N⁶-cyclopentyladenosine ([³H]CCPA) to human adenosine A₁ receptors was reduced to only 10% in the presence of 10 μM SCH-202676⁷. Gao et al. found that the dissociation of the antagonist [³H]DPCPX was decreased almost 4 times by the presence of SCH-202676⁸.

These binding experiments showed us that the human adenosine A₁YFP receptor retains its pharmacological profile and that the allosteric modulator PD81,723 and SCH-202676 have the same effect on the wt and the YFP-tagged adenosine A₁ receptor.

As reviewed in Chapter 2, desensitization and presumed internalization of adenosine A₁ receptors after long term exposure to (*R*)-*N*⁶-(2-Phenylisopropyl)adenosine (*R*-PIA) was observed earlier in other tissues such as rat brain¹³, DDT₁MF-2 cells^{12,15} and rat adipocytes²⁹. Human adenosine A₁ receptors, stably expressed in HEK293 cells and pretreated with 10 μM CPA for 24 h showed a downregulation of 48%¹⁶. In these experiments, the desensitization was quantified using radioligand binding experiments on plasma membranes. Here, we describe the internalization of the human adenosine A₁YFP receptor in CHO cells induced by different concentrations of CPA and monitored by confocal microscopy, and confirm the results with radioligand binding experiments. After 16 hours of incubation with 400 nM CPA, which is approximately 10 × K_i of CPA, 25% of the receptors were internalized. It is striking that CPA is not able to induce receptor internalization at a concentration of 40 nM, close to CPA's K_i value (42.5 nM) at which half of the receptor population is assumed to be occupied. This is in contrast to DDT₁MF-2 cells exposed to 50 nM *R*-PIA for 12-24 h, which showed clear internalization¹². The K_i value of *R*-PIA for the adenosine A₁ receptor in DDT₁MF-2 cells is 76 nM¹⁵. This difference may be explained to a different regulation of receptor internalization for each cell type adenosine A₁ receptors are expressed in. Apparently, over 50% of the human adenosine A₁YFP receptors have to be occupied by CPA before the receptors start to cluster, subsequently followed by internalization. Internalization became more apparent (40%) at a concentration of 4 μM CPA (approx. 100 × K_i). Radioligand binding experiments performed on membranes of this incubation confirmed this percentage (32 ± 1%). In the presence of the allosteric enhancer PD81,723 (10 μM), however, some internalization (11%) was already observed at a concentration of 40 nM CPA. The internalization at 400 nM and 4 μM became more distinct in the presence of 10 μM PD81,723 (59% and 61% respectively). Allosteric enhancers, such as PD81,723, have the property that they bind to a site distinct from the orthosteric ligand binding site. By doing so, they change the 3D-conformation of the receptor and facilitate ligand binding. In other words, they enhance the affinity of agonists for the receptor. Our data show that this change in receptor conformation, induced by PD81,723, also enhances clustering and internalization of de human adenosine A₁YFP receptor upon agonist binding, thereby increasing the amount of internalized receptors. This results in a higher percentage of internalized receptors in the presence of PD81,723 at the same CPA concentration. The action of PD81,723

is synergistic. PD81,723 (10 μM) alone has no effect on receptor distribution. This is in accordance with Bhattacharya and Linden²⁷ who did not observe a decrease in membrane binding sites after 24 h of pretreatment with 20 μM PD81,723. Pretreatment of CHO cells stably expressing recombinant human adenosine A₁ receptors with either 10 μM CPA or 10 μM CPA plus 20 μM PD81,723 resulted in a loss of membrane binding sites of over 40%.

Recently, it has been shown that the enzyme adenosine deaminase (ADA) acted as a receptor activity modifying protein (RAMP) on the adenosine A₁ receptor, and stimulated *R*-PIA induced A₁ receptor internalization²⁴. Thus, ADA also appears to regulate A₁ receptor function allosterically. However, the role of ADA was different compared to that of PD81,723. ADA accelerated the internalization of adenosine A₁ receptors, $t_{1/2}$ decreased from 10 h to 2.9 h¹⁴, whereas PD81,723 lowers the threshold of agonist concentration at which internalization occurs. ADA did not increase the number of receptors which are internalized²⁵, whereas PD81,723 increases the percentage of internalized receptors from 40% to 61% at the highest concentration of CPA tested (4 μM).

Next to the allosteric enhancer PD81,723 we also studied SCH-202676. In contrast to PD81,723, SCH-202676 (10 μM) completely prevented the internalization of the human adenosine A₁YFP receptors at all CPA concentrations, except for 4 μM CPA. At the highest CPA concentration, some clustering of human adenosine A₁YFP receptors was observed (10%). Even at a concentration of 4 μM CPA, the percentage of occupied receptors is not high enough to induce substantial internalization due to the presence of 10 μM SCH-202676. To the best of our knowledge the effects of this modulator on receptor processing have not been addressed before.

In conclusion, in this study we present the effect of the allosteric modulator PD81,723 and SCH-202676 on the internalization of the human adenosine A₁ receptor. PD81,723, an allosteric enhancer, is able to lower the threshold of agonist concentration for inducing internalization. Already at a concentration of 40 nM CPA, some internalization is observed. On the contrary, SCH-202676 is a strong inhibitor of agonist binding, thereby preventing internalization of the human adenosine A₁YFP receptors.

Acknowledgements

The peYFP-N1 vector was kindly provided by dr. C. Backendorf (Department of Molecular Genetics, Leiden Institute of Chemistry, Leiden University).

References

1. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol. Rev.* 53:527-552.
2. Soudijn W, van Wijngaarden I, IJzerman AP. (2002) Allosteric modulation of G protein-coupled receptors. *Curr Opin Drug Discov Devel.* 5:749-55.
3. Christopoulos A. and Kenakin T. (2002) G protein-coupled receptor allosterism and complexing. *Pharmacol. Rev.* 54:323-374.
4. Musser B, Mudumbi RV, Liu J, Olson RD, Vestal RE. (1999) Adenosine A₁ receptor-dependent and -independent effects of the allosteric enhancer PD81,723. *J. Pharmacol. Exp. Ther.* 288:446-454.
5. Kollias-Baker CA, Ruble J, Jacobson M, Harrison JK, Ozeck M, Shryock JC, Belardinelli. (1997) Agonist-independent effect of an allosteric enhancer of the A₁ adenosine receptor in CHO cells stably expressing the recombinant human A₁ receptor. *J. Pharmacol. Exp. Ther.* 281:761-768.
6. Fawzi AB, Macdonald D, Benbow LL, Smith Torhan A, Zhang H, Weig BC, Ho G, Tulshian D, Linder ME, Graziano MP. (2001) SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. *Mol. Pharmacol.* 59:30-37.
7. Van den Nieuwendijk AM, Pietra D, Heitman L, Göblyös A, IJzerman AP. (2004) Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. *J. Med. Chem.* 47:663-672.
8. Gao ZG, Gross AS, Jacobson KA. (2004) Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. *Life Sci.* 74:3173-3780.
9. Göblyös A, de Vries H, Brussee J, IJzerman AP. (2005) Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A₁ receptors and their molecular mechanism of action. *J. Med. Chem.* 48:1145-1151.
10. Lewandowicz AM, Vepsäläinen J, Laitinen JT. (2006) The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphhydryl-sensitive mechanisms. *Br. J. Pharmacol.* 147:422-429.
11. Koenig JA and Edwardson JM. (1997) Endocytosis and recycling of G protein-coupled receptors. *Trends Pharmacol Sci.* 18:276-287.
12. Ciruela F, Saura C, Canela EI, Mallol J, Lluís C, Franco R. (1997) Ligand-induced phosphorylation, clustering, and desensitization of A₁ adenosine receptors. *Mol. Pharmacol.* 52: 788-797.
13. Ruiz A, Sanz JM, Gonzalez-Calero G, Fernandez M, Andres A, Cubero A, Ros M. (1996) Desensitization and internalization of adenosine A₁ receptors in rat brain by in vivo treatment with R-PIA: involvement of coated vesicles. *Biochim. Biophys. Acta* 1310:168-174.
14. Saura CA, Mallol J, Canela EI, Lluís C, Franco R. (1998) Adenosine deaminase and A₁ adenosine receptors internalize together following agonist-induced receptor desensitisation. *J. Biol. Chem.* 273:17610-17617.
15. Nie Z, Mei Y, Ramkumar V. (1997) Short term desensitization of the A₁ adenosine receptors in DDT₁MF-2 cells. *Mol. Pharmacol.* 52:456-464.
16. Gao Z, Ni Y, Szabo G, Linden J. (1999) Palmitoylation of the recombinant human A₁ adenosine receptor: enhanced proteolysis of palmitoylation-deficient mutant receptors. *Biochem. J.* 342:387-395.
17. Ferguson G, Watterson KR, Palmer TM. (2000) Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases. *Mol. Pharmacol.* 57:546-552.
18. Van der Klein PA, Kourounakis AP, IJzerman AP. (1999) Allosteric modulation of the adenosine A₁ receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. *J. Med. Chem.* 42:3629-3635.
19. Beukers MW, van Oppenraaij J, van der Hoorn PP, Blad CC, den Dulk H, Brouwer J, IJzerman AP. (2004) Random mutagenesis of the human adenosine A_{2B} receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. *Mol. Pharmacol.* 65:702-710.
20. Townsend-Nicholson A. and Shine J. (1992) Molecular cloning and characterisation of a human brain A₁ adenosine receptor cDNA. *Mol. Brain. Res.* 16:365-370.
21. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. (1985) Measurement of protein using bicinchoninic acid. *Anal. Biochem.* 150:76-85.

22. Kourounakis A, Visser C, de Groote M, IJzerman AP. (2001) Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A₁ receptor. *Biochem. Pharmacol.* 61:137-144.
23. Cheng Y, Prusoff WH. (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (IC₅₀) of an enzymatic reaction. *Biochem. Pharmacol.* 22:3099-3108.
24. Navarro A, Zapata R, Canela E I, Mallol J, Lluís C, Franco R. (1999) Epidermal growth factor (EGF)-induced up-regulation and agonist- and antagonist-induced desensitization and internalization of A₁ adenosine receptors in a pituitary-derived cell line. *Brain Res.* 816:47-57.
25. Escriche M, Burgueno J, Ciruela F, Canela EI, Mallol J, Enrich C, Lluís C, Franco R. (2003) Ligand-induced caveolae-mediated internalization of A₁ adenosine receptors: morphological evidence of endosomal sorting and receptor recycling. *Exp. Cell. Res.* 285:72-90.
26. Gines S, Ciruela F, Burgueno J, Casado V, Canela EI, Mallol J, Lluís C, Franco R. (2001) Involvement of caveolin in ligand-induced recruitment and internalization of A₁ adenosine receptor and adenosine deaminase in an epithelial cell line. *Mol. Pharmacol.* 59:1314-1323.
27. Battacharya S. and Linden J. (1996) Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A₁ adenosine receptors. *Mol. Pharmacol.* 50:104-111.
28. Dalpiaz A, Townsend-Nicholson A, Beukers MW, Schofield PR, IJzerman AP. (1998) Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A₁ receptors. *Biochem Pharmacol.* 56:1437-1445.
29. Longabaugh JP, Didsbury J, Spiegel A, Stiles GL. (1989) Modification of the rat adipocyte A₁ adenosine receptor-adenylate cyclase system during chronic exposure to an A₁ adenosine receptor agonist: alterations in the quantity of G_sα and G_iα are not associated with changes in their mRNAs. *Mol. Pharmacol.* 36:681-688.